CompletedNot Applicable

Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]

63 participantsStarted 2007-01

Plain-language summary

The purpose of this survey is to evaluate the safety (that is, frequency of adverse events) and efficacy (that is, hemostatic effect, rate of rebleeding after confirmation of hemostasis) of administration of lansoprazole intravenous 30 milligram (mg) (Takepron Intravenous 30 mg ) to a large number of participants with acute stress ulcer or acute gastric mucosal lesion in daily medical practice.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Inclusion Criteria: Participants with the following diseases for whom oral administration is not feasible: Acute stress ulcer, and acute gastric mucosal lesions (both of which should be accompanied by bleeding). Exclusion Criteria: \-

What they're measuring

Number of Participants Reporting One or More Adverse Drug Reactions

Timeframe: Baseline up to Week 9

Trial details

NCT IDNCT02170207

SponsorTakeda

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2010-03

Results submitted2016-02-08

View on ClinicalTrials.gov More Acute Stress Ulcer and Acute Gastric Mucosal Lesions trials